Ionis Pharmaceuticals (IONS) Operating Leases (2021 - 2026)

Ionis Pharmaceuticals' Operating Leases history runs 6 years deep, the most recent figure standing at $259.2 million for Q1 2026.

• In Q1 2026, Operating Leases rose 62.63% year-over-year to $259.2 million; the TTM figure through Mar 2026 stood at $259.2 million (up 62.63% YoY), while the FY2025 annual figure was $262.4 million, up 62.16% from the prior year.
• Operating Leases was $259.2 million for Q1 2026 at Ionis Pharmaceuticals, down from $262.4 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $262.7 million in Q3 2025 to a low of $159.4 million in Q1 2025.
• Historically, Operating Leases has averaged $189.2 million across 5 years, with a median of $172.0 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Operating Leases soared 820.86% in 2022, then dropped 5.5% in 2025.
• A 5-year view of Operating Leases shows it stood at $178.9 million in 2022, then decreased by 4.51% to $170.9 million in 2023, then dropped by 5.31% to $161.8 million in 2024, then surged by 62.16% to $262.4 million in 2025, then decreased by 1.21% to $259.2 million in 2026.
• The last three Operating Leases figures came in at $259.2 million (Q1 2026), $262.4 million (Q4 2025), and $262.7 million (Q3 2025), per Business Quant data.